Security
NeOnc Technologies Holdings, Inc. Common Stock · NTHI
NTHINASDAQCommon stockCurrentCIK 1979414Updated Nov 14, 2026
NTHI price & chart
Loading TradingView…
NASDAQ:NTHI on TradingView ↗About the company
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.
In the news
Biotech Brainiacs and Breakthroughs ↗
Recent filings
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
4 filing
4 filing
Show 5 more recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| AssetsUSD | 4,082,916Source | — | 5,231,792Source | 2,988,187Source | — | 3,330,161Source | 8,441,691Source | — | 2,823,634Source | 3,417,241Source |
| Current assets: | ||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,513,224Source | — | 1,973,420Source | 125,039Source | — | 138,601Source | 5,439,210Source | — | 58,729Source | 64,893Source |
| Assets, CurrentUSD | 2,961,576Source | — | 4,190,280Source | 1,653,942Source | — | 2,095,163Source | 7,360,191Source | — | 1,388,711Source | 2,195,203Source |
| Prepaid Expense and Other Assets, CurrentUSD | 677,246Source | — | 1,213,084Source | 760,219Source | — | 1,173,901Source | 1,152,297Source | — | 583,096Source | 386,559Source |
| Operating Lease, Right-of-Use AssetUSD | 379,509Source | — | 322,049Source | 397,817Source | — | 340,639Source | — | — | 361,045Source | 23,526Source |
| LIABILITIES AND EQUITY | ||||||||||
| LiabilitiesUSD | 15,897,186Source | — | 23,761,103Source | 14,803,681Source | — | 16,561,326Source | — | — | 20,331,363Source | 8,922,202Source |
| Stockholders’ equity: | ||||||||||
| Common Stock, Value, IssuedUSD | 1,948Source | — | 2,594Source | 1,903Source | — | 2,483Source | 1,903Source | — | 2,198Source | 1,809Source |
| Retained Earnings (Accumulated Deficit)USD | -97,230,551Source | — | -135,814,631Source | -88,614,631Source | — | -121,574,587Source | -88,610,432Source | — | -112,754,655Source | -50,608,445Source |
| Stockholders' Equity Attributable to ParentUSD | -11,814,270Source | -5,267,392Source | -18,529,311Source | -11,815,494Source | -6,208,513Source | -13,231,165Source | -9,623,645Source | -16,927,229Source | -17,507,729Source | -5,504,961Source |
| Additional Paid in Capital, Common StockUSD | 85,414,333Source | — | 122,070,460Source | 76,797,234Source | — | 114,418,658Source | 78,984,884Source | — | 97,951,035Source | 45,101,675Source |
| Liabilities and EquityUSD | 4,082,916Source | — | 5,231,792Source | 2,988,187Source | — | 3,330,161Source | 8,441,691Source | — | 2,823,634Source | 3,417,241Source |
| Current liabilities: | ||||||||||
| Liabilities, CurrentUSD | 15,588,322Source | — | 23,506,555Source | 14,476,802Source | — | 16,287,621Source | 18,065,336Source | — | 20,040,681Source | 8,922,202Source |
| Operating Lease, Liability, CurrentUSD | 69,877Source | — | 73,669Source | 68,633Source | — | 72,348Source | — | — | 71,131Source | 24,722Source |
| Operating Lease, Liability, NoncurrentUSD | 308,864Source | — | 254,548Source | 326,879Source | — | 273,705Source | — | — | 290,682Source | — |
| Preferred Stock, Value, Issued | — | — | —Source | — | — | — | — | — | — | — |
| Accounts Payable, Current | — | — | — | —Source | — | — | —Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -8,615,920Source | -2,184,500Source | -14,240,044Source | -5,680,170Source | -8,819,932Source | -32,326,016Source | -62,146,210Source | -11,898,464Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 5,040,246Source | — | 5,651,913Source | 3,526,076Source | 2,732,397Source | 17,397,774Source | 35,555,059Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,991,773Source | -5,650,055Source | -20,363,948Source | -4,213,916Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -500,000Source | — |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,071,645Source | 11,024,372Source | 20,857,784Source | 4,246,947Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,513,224Source | 1,334,627Source | 1,973,420Source | 125,039Source | 138,601Source | 5,439,210Source | 58,729Source | 64,893Source |
| Additional Financial Items | ||||||||||
| AmortizationUSD | — | — | 438,111Source | 67,076Source | 6,944Source | 0Source | 11,574Source | 0Source | 1,110,484Source | 391,041Source |
| Amortization of Debt Issuance CostsUSD | — | — | 438,111Source | — | 167,951Source | 192,249Source | 192,165Source | 167,951Source | 1,110,484Source | 145,097Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 192,165Source | 577,192Source | 1,110,484Source | 145,097Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 2,069,923Source |
| General and Administrative ExpenseUSD | — | — | 902,985Source | 243,659Source | 895,559Source | 984,262Source | 488,709Source | 849,485Source | 4,817,900Source | 1,679,660Source |
| LitigationSettlementLossUSD | — | — | 380,162Source | — | — | — | 2,801Source | — | 689,543Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,615,920Source | -2,184,500Source | -14,240,044Source | -5,680,170Source | -8,819,932Source | -32,326,016Source | -62,146,210Source | -11,898,464Source |
| Operating ExpensesUSD | — | — | 6,934,647Source | 2,197,187Source | 14,069,887Source | 5,708,034Source | 7,055,662Source | 31,940,832Source | 58,280,435Source | 7,225,522Source |
| Operating Lease, ExpenseUSD | — | — | 21,781Source | 102,704Source | 21,668Source | 15,581Source | 21,688Source | 24,722Source | 65,614Source | 245,944Source |
| Amortization of Intangible Assets | — | — | — | — | —Source | — | — | — | — | — |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | —Source | — | —Source | — | — | — |
| Investment Income, Interest | — | — | — | — | — | — | — | —Source | — | — |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | —Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 0Source | — | — | 39,990Source | 39,990Source | 83,000Source |
| Operating Income (Loss)USD | — | — | -6,934,647Source | -2,197,187Source | -14,069,887Source | -5,708,034Source | -7,055,662Source | -31,900,842Source | -58,240,445Source | -7,142,522Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,615,920Source | -2,184,500Source | -14,240,044Source | -5,680,170Source | -8,819,932Source | -32,326,016Source | -62,146,210Source | -11,898,464Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.45Source | -0.12Source | -0.58Source | -0.3Source | -0.38Source | -1.78Source | -3.2Source | -0.69Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.45Source | -0.12Source | -0.58Source | -0.3Source | -0.38Source | -1.78Source | -3.2Source | -0.69Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 19,211,745Source | 17,918,330Source | 24,663,745Source | 19,026,776Source | 23,293,453Source | 18,135,317Source | 19,398,776Source | 17,342,755Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 19,211,745Source | 17,918,330Source | 24,663,745Source | 19,026,776Source | 23,293,453Source | 18,135,317Source | 19,398,776Source | 17,342,755Source |
| Additional Financial Items | ||||||||||
| General and Administrative ExpenseUSD | — | — | 902,985Source | 243,659Source | 895,559Source | 984,262Source | 488,709Source | 849,485Source | 4,817,900Source | 1,679,660Source |
| Interest and Other IncomeUSD | — | — | — | — | 483,112Source | 28,725Source | 52,319Source | 51,699Source | 398,830Source | 16,133Source |
| Interest ExpenseUSD | — | — | 869,815Source | — | 234,370Source | 48,750Source | 982,624Source | 308,922Source | 2,504,567Source | 2,557,055Source |
| Interest Expense, DebtUSD | — | — | — | — | 0Source | — | 725,601Source | — | 2,243,066Source | — |
| Interest Income, OtherUSD | — | — | 6,815Source | 12,687Source | 334Source | 28,725Source | 5,196Source | 51,699Source | 327,582Source | 16,133Source |
| Labor and Related ExpenseUSD | — | — | 182,268Source | 186,149Source | 268,797Source | 163,887Source | 189,228Source | 161,494Source | 686,498Source | 686,131Source |
| LitigationSettlementLossUSD | — | — | 380,162Source | — | — | — | 2,801Source | — | 689,543Source | — |
| Operating ExpensesUSD | — | — | 6,934,647Source | 2,197,187Source | 14,069,887Source | 5,708,034Source | 7,055,662Source | 31,940,832Source | 58,280,435Source | 7,225,522Source |
| Operating Lease, ExpenseUSD | — | — | 21,781Source | 102,704Source | 21,668Source | 15,581Source | 21,688Source | 24,722Source | 65,614Source | 245,944Source |
| Other General and Administrative ExpenseUSD | — | — | 532,359Source | 253,348Source | 569,952Source | 593,609Source | 251,968Source | 143,684Source | 2,987,110Source | 842,256Source |
| Other IncomeUSD | — | — | -6,815Source | -12,687Source | 482,778Source | -240,138Source | 47,123Source | — | 71,247Source | — |
| Research and Development ExpenseUSD | — | — | 715,038Source | 956,725Source | 2,649,673Source | 677,332Source | 1,286,336Source | 998,222Source | 3,638,257Source | 3,045,239Source |
| Selling, General and Administrative Expense | — | — | — | — | — | — | — | —Source | — | — |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — |
| Amortization of Intangible Assets | — | — | — | — | —Source | — | — | — | — | — |
| Current Income Tax Expense (Benefit) | — | — | — | — | —Source | —Source | —Source | —Source | — | — |
| Investment Income, Interest | — | — | — | — | — | — | — | —Source | — | — |
| Other Expenses | — | — | — | — | — | — | —Source | — | — | — |
| Other Operating Income | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-296788
Registration 333-294999
Registration 333-294845
Registration 333-293281
Filing attachments
neonctechnologies_ex99-1.htm · 8-K · 2026-11-13
Exhibit 99.1 NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases 2026 open-market purchases total 271,000 shares for approximately $1.11 million CALABASAS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, today announced that Amir F. Heshmatpour, its Executive Chairman, President and Chief Executive Officer, purchased 80,000 shares of…
Read attachment ↗neonctechnologies_ex99-2.htm · 8-K · 2026-11-13
Exhibit 99.2 NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company…
Read attachment ↗neonctechnologies_ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual Meeting on November 13 CALABASAS, Calif., Nov. 05, 2026 - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced financi…
Read attachment ↗neonctechnologies_ex99-1.htm · 8-K · 2026-11-03
Exhibit 99.1 NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology CALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on Frid…
Read attachment ↗neonctechnologies_ex99-1.htm · 8-K · 2026-10-22
Exhibit 99.1 NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of investigational treatment CALABASAS, Calif., Oct. 16, 2026 - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous s…
Read attachment ↗neonctechnologies_ex99-2.htm · 8-K · 2026-10-22
Exhibit 99.2 NeOnc Technologies and the Department of Health - Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi Two children in Abu Dhabi are receiving investigational NEO100 through NeOnc’s Compassionate Care program, with a third expected this week …
Read attachment ↗